INTERCEPT Blood System Highlighted at the International Society of Blood Transfusion (ISBT)
June 21 2017 - 8:30AM
Business Wire
Evidence supporting the use of INTERCEPT
continues to grow with multiple presentations and abstracts at
ISBT
Cerus Corporation (NASDAQ:CERS) announced results of 16
abstracts presenting experiences with the INTERCEPT Blood System
for platelets, plasma, and red blood cells during the 27th Regional
Congress of the International Society of Blood Transfusion (ISBT)
in Copenhagen, Denmark held from June 17 to June 21, 2017. ISBT is
one of the premier congresses in blood transfusion science and
medicine.
“These studies continue to build the body of evidence
demonstrating robust pathogen inactivation performance across the
full portfolio of INTERCEPT treated blood components,” noted Dr.
Richard Benjamin, Cerus' chief medical officer. “In addition, data
presented at ISBT support the European launch of our triple storage
container platelet set, showing comparable performance to existing
sets while improving economics and operational efficiencies. Data
on INTERCEPT red cells continues to demonstrate strong product
performance and potentially provides the opportunity to replace
gamma irradiation and red cell washing. Lastly, pathogen
inactivated cryoprecipitate plasma addresses an important unmet
clinical need to correct for fibrinogen deficit in surgery, trauma,
and maternal hemorrhage.”
Key presentations of interest include:
- Pathogen Inactivation of Zika,
Dengue, and Chikungunya Viruses In All Blood Components, by D
Musso, F Santa Maria, A Laughhunn et al: New data combined with
previous published studies show that INTERCEPT inactivates Zika,
Dengue, and Chikungunya viruses to the limit of detection in
plasma, platelet, and red blood cell components.
- Storage Study of Apheresis Platelets
In Additive Solution After Photochemical Treating Using a Novel
Triple Storage Set, by A Lotents, N de Valensart, S Acqart, F
Cognasse, T Najdovski, A Rapaille: Apheresis platelets collected
and stored with the triple set compared to the single set showed no
significant difference in in vitro platelet function after
INTERCEPT treatment for up to seven days of storage.
- Evaluation of Pathogen Reduced
(Amotosalen-UVA) Pooled Cryoprecipitate and Cryoprecipitate-Poor
Plasma, by L Amorim, T Ferreira, J Oliveira, F Azevedo, A
Oliveira, M Lopes: For patients in need of cryoprecipitate and
cryoprecipitate-poor plasma, pathogen inactivation improves both
safety and availability. In addition, the authors make the case for
the system to improve overall cryoprecipitate production at a lower
cost.
- Robustness of the INTERCEPT Blood
System for Red Blood Cells, by A Erickson, M Schott, B
Warbington, G Villegas, D Hanson, N Mufti: Red blood cell units
treated with pathogen inactivation met the European Directorate for
the Quality of Medicines & Healthcare (EDQM) guidelines with
respect to hematocrit, hemoglobin content and hemolysis at end of
storage.
- Implementation of double dose
pathogen-inactivated platelets in routine with productivity
and cost optimization, by MB S. Madsen: By replacing gamma
irradiation and bacterial detection, converting to production of
double-dose buffy coat platelets, and replacing automated platelet
production with manual processing, the Blood Center of the Aalborg
University Hospital has demonstrated the ability to produce
INTERCEPT platelets with a 13% reduction in cost compared to their
prior conventional platelet supply.
A full list of abstracts can be viewed at
www.cerus.com/Events/news-and-events/ISBT-Copenhagen/.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in
the field of blood transfusion safety. The INTERCEPT Blood System
is designed to reduce the risk of transfusion-transmitted
infections by inactivating a broad range of pathogens such as
viruses, bacteria and parasites that may be present in donated
blood. The nucleic acid targeting mechanism of action of the
INTERCEPT treatment is designed to inactivate established
transfusion threats, such as Hepatitis B and C, HIV, West Nile
Virus and bacteria, as well as emerging pathogens such as
chikungunya, malaria and dengue. Cerus currently markets and sells
the INTERCEPT Blood System for both platelets and plasma in the
United States, Europe, the Commonwealth of Independent States, the
Middle East and selected countries in other regions around the
world. The INTERCEPT red blood cell system is in clinical
development. See www.cerus.com for information about Cerus.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170621005444/en/
Cerus CorporationLainie Corten - Vice President, Global
Marketing & Investor RelationsTim Lee - Investor Relations
Director(925) 288-6137ir@cerus.com
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2023 to Apr 2024